222 related articles for article (PubMed ID: 24589724)
1. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Siwy J; Schanstra JP; Argiles A; Bakker SJ; Beige J; Boucek P; Brand K; Delles C; Duranton F; Fernandez-Fernandez B; Jankowski ML; Al Khatib M; Kunt T; Lajer M; Lichtinghagen R; Lindhardt M; Maahs DM; Mischak H; Mullen W; Navis G; Noutsou M; Ortiz A; Persson F; Petrie JR; Roob JM; Rossing P; Ruggenenti P; Rychlik I; Serra AL; Snell-Bergeon J; Spasovski G; Stojceva-Taneva O; Trillini M; von der Leyen H; Winklhofer-Roob BM; Zürbig P; Jankowski J
Nephrol Dial Transplant; 2014 Aug; 29(8):1563-70. PubMed ID: 24589724
[TBL] [Abstract][Full Text] [Related]
2. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.
Lindhardt M; Persson F; Currie G; Pontillo C; Beige J; Delles C; von der Leyen H; Mischak H; Navis G; Noutsou M; Ortiz A; Ruggenenti PL; Rychlik I; Spasovski G; Rossing P
BMJ Open; 2016 Mar; 6(3):e010310. PubMed ID: 26936907
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.
Tofte N; Lindhardt M; Adamova K; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Kooy A; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Ruggenenti PL; Rutters F; Rychlík I; Spasovski G; Speeckaert M; Trillini M; von der Leyen H; Rossing P
Diabet Med; 2018 Oct; 35(10):1375-1382. PubMed ID: 29781558
[TBL] [Abstract][Full Text] [Related]
4. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
[TBL] [Abstract][Full Text] [Related]
5. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
7. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
Currie GE; von Scholten BJ; Mary S; Flores Guerrero JL; Lindhardt M; Reinhard H; Jacobsen PK; Mullen W; Parving HH; Mischak H; Rossing P; Delles C
Cardiovasc Diabetol; 2018 Apr; 17(1):50. PubMed ID: 29625564
[TBL] [Abstract][Full Text] [Related]
8. [Early detection by urinary proteome analysis : A new concept in patient management of diabetic nephropathy].
Beige J; Drube J; von der Leyen H; Pape L; Rupprecht H
Internist (Berl); 2020 Oct; 61(10):1094-1105. PubMed ID: 32897404
[TBL] [Abstract][Full Text] [Related]
9. Urinary proteomics for early diagnosis in diabetic nephropathy.
Zürbig P; Jerums G; Hovind P; Macisaac RJ; Mischak H; Nielsen SE; Panagiotopoulos S; Persson F; Rossing P
Diabetes; 2012 Dec; 61(12):3304-13. PubMed ID: 22872235
[TBL] [Abstract][Full Text] [Related]
10. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
Oellgaard J; Gæde P; Persson F; Rossing P; Parving HH; Pedersen O
J Diabetes Complications; 2018 Dec; 32(12):1133-1140. PubMed ID: 30282584
[TBL] [Abstract][Full Text] [Related]
11. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
Critselis E; Lambers Heerspink H
Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
[TBL] [Abstract][Full Text] [Related]
12. Changes in urine proteome accompanying diabetic nephropathy progression.
Lewandowicz A; Bakun M; Kohutnicki R; Fabijańska A; Kistowski M; Imiela J; Dadlez M
Pol Arch Med Wewn; 2015; 125(1-2):27-38. PubMed ID: 25578432
[TBL] [Abstract][Full Text] [Related]
13. Urinary afamin levels are associated with the progression of diabetic nephropathy.
Kaburagi Y; Takahashi E; Kajio H; Yamashita S; Yamamoto-Honda R; Shiga T; Okumura A; Goto A; Fukazawa Y; Seki N; Tobe K; Matsumoto M; Noda M; Unoki-Kubota H
Diabetes Res Clin Pract; 2019 Jan; 147():37-46. PubMed ID: 29522788
[TBL] [Abstract][Full Text] [Related]
14. The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.
Verbeke F; Siwy J; Van Biesen W; Mischak H; Pletinck A; Schepers E; Neirynck N; Magalhães P; Pejchinovski M; Pontillo C; Lichtinghagen R; Brand K; Vlahou A; De Bacquer D; Glorieux G
Nephrol Dial Transplant; 2021 Apr; 36(5):811-818. PubMed ID: 31837226
[TBL] [Abstract][Full Text] [Related]
15. Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice.
Klein J; Ramirez-Torres A; Ericsson A; Huang Y; Breuil B; Siwy J; Mischak H; Peng XR; Bascands JL; Schanstra JP
Kidney Int; 2016 Nov; 90(5):1045-1055. PubMed ID: 27528550
[TBL] [Abstract][Full Text] [Related]
16. Assessment of two novel renal tubular proteins in type 2 diabetic patients with nephropathy.
Abdel Ghafar MT; Shalaby KH; Okda HI; Abo El Gheit RE; Soliman NA; Keshk WA
J Investig Med; 2020 Mar; 68(3):748-755. PubMed ID: 31722957
[TBL] [Abstract][Full Text] [Related]
17. Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy.
Ye H; Bai X; Gao H; Li L; Wu C; Sun X; Zhang C; Shen Y; Zhang J; Lu Z
J Diabetes Complications; 2014; 28(1):96-100. PubMed ID: 24075693
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
Curovic VR; Eickhoff MK; Rönkkö T; Frimodt-Møller M; Hansen TW; Mischak H; Rossing P; Ahluwalia TS; Persson F
Diabetes Care; 2022 Nov; 45(11):2662-2668. PubMed ID: 35998283
[TBL] [Abstract][Full Text] [Related]
19. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy.
Jiang H; Guan G; Zhang R; Liu G; Cheng J; Hou X; Cui Y
Diabetes Metab Res Rev; 2009 Mar; 25(3):232-41. PubMed ID: 19177462
[TBL] [Abstract][Full Text] [Related]
20. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
Li Z; Xu Y; Liu X; Nie Y; Zhao Z
Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
